

## PART B - FEE(S) TRANSMITTAL

BEST AVAILABLE COPY

Complete and send this form together with applicable fee(s), to: Mail

DEC 06 2004

or Fax

Mail Stop ISSUE FEE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 (703) 746-4000

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

23913 7590 09/03/2004

Pfizer Inc.  
 150 EAST 42ND STREET  
 5TH FLOOR - STOP 49  
 NEW YORK, NY 10017-5612

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

## Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.

Krishna G. Banerjee, Ph.D.	(Depositor's name)
Krishna G. Banerjee	(Signature)
November 30, 2004	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/844,646	04/27/2001	Bingwei V. Yang	PC 10839A	1585

TITLE OF INVENTION: SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTIPIROLIFERATIVE AGENTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$300	\$1630	12/03/2004
EXAMINER	ART UNIT	CLASS-SUBCLASS			
SEAMAN, D MARGARET M	1625	514-312000			

Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

2. For printing on the patent front page, list  
 (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  
 (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

- 1 Peter C. Richardson
- 2 Krishna G. Banerjee
- 3 Garth Butterfield

## I. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

## (A) NAME OF ASSIGNEE

## (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Pfizer Inc.

New York, NY

Please check the appropriate assignee category or categories (will not be printed on the patent):  Individual  Corporation or other private group entity  Government

## 4a. The following fee(s) are enclosed:

## 4b. Payment of Fee(s):

- Issue Fee  
 Publication Fee (No small entity discount permitted)  
 Advance Order - # of Copies \_\_\_\_\_

- A check in the amount of the fee(s) is enclosed.  
 Payment by credit card. Form PTO-2038 is attached.  
 The Director is hereby authorized to charge the required fee(s), or credit any overpayment, to Deposit Account Number 16-1445 (enclose an extra copy of this form).

## 5. Change in Entity Status (from status indicated above)

- a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

0944645

Authorized Signature Krishna G. BanerjeeDate November 30, 2004Typed or printed name Krishna G. Banerjee, PhDRegistration No. 43,317

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

12/07/2004 RHEBRAH1 00000100 161445

 1370.00 DA  
 300.00 DR  
 01 FC:1501  
 02 FC:1504



PATENT  
Docket No.: PC10839A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **YANG ET AL.**

APPLICATION NO.: **09/844,646** : Examiner: **Seaman, Margaret M**

FILING DATE: **APRIL 27, 2001** : Group Art Unit: **1625**

TITLE: **SUBSTITUTED QUINOLIN-ZONE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS** :

Mail Stop ISSUE FEE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

ISSUE FEE TRANSMITTAL

This document responds to the Notice of Allowance and Issue Fee Due form mailed to Applicants' attorney on September 3, 2004.

Attached to this document is the original part B of the above form.

Respectfully submitted,

Date: November 30, 2004

Pfizer Inc  
Patent Department, 150-5-49  
235 East 42nd Street  
New York, NY 10017-5755  
(212) 733-6031

*Krishna G. Banerjee*  
**Krishna G. Banerjee, Ph.D.**  
Attorney for Applicants  
Reg. No. 43,317